| aminoglycoside therapy (N = 319) | no aminoglycoside therapy (N = 96) | p value |
Cardiovascular disease |
|
| 0.079 |
no | 270 (84.6%) | 88 (91.7%) |
|
yes | 49 (15.4%) | 8 (8.3%) |
|
Lung disease |
|
| 0.968 |
no | 306 (95.9%) | 92 (95.8%) |
|
yes | 13 (4.1%) | 4 (4.2%) |
|
Kidney disease |
|
| 0.583 |
no | 318 (99.7%) | 96 (100.0%) |
|
yes | 1 (0.3%) | 0 (0.0%) |
|
Neurological disease |
|
| 0.200 |
no | 317 (99.4%) | 94 (97.9%) |
|
yes | 2 (0.6%) | 2 (2.1%) |
|
Immobility |
|
| 0.200 |
no | 317 (99.4%) | 94 (97.9%) |
|
yes | 2 (0.6%) | 2 (2.1%) |
|
Cancer |
|
| 0.437 |
no | 317 (99.4%) | 96 (100.0%) |
|
yes | 2 (0.6%) | 0 (0.0%) |
|
Diabetes type 2 |
|
| 0.096 |
no | 310 (97.2%) | 96 (100.0%) |
|
yes | 9 (2.8%) | 0 (0.0%) |
|
Other diseases |
|
| 0.894 |
no | 284 (89.0%) | 85 (88.5%) |
|
yes | 35 (11.0%) | 11 (11.5%) |
|
ASA score |
|
| 0.275 |
I | 169 (53.8%) | 58 (61.1%) |
|
II | 118 (37.6%) | 34 (35.8%) |
|
III | 24 (7.6%) | 3 (3.2%) |
|
IV | 3 (1.0%) | 0 (0.0%) |
|
Complications |
|
| 0.561 |
no | 268 (84.0%) | 83 (86.5%) |
|
yes | 51 (16.0%) | 13 (13.5%) |
|